Expert Analysis

CME

Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 16, 2021

Expiration: February 15, 2022

Amy E. DeZern
Amy E. DeZern, MD, MHS
Srdan Verstovsek
Srdan Verstovsek, MD, PhD

Activity

Progress
1
Course Completed
Key Studies in MPN and MDS

In this module, Srdan Verstovsek, MD, PhD, and Amy E. DeZern, MD, MHS, offer an overview of some of the myeloproliferative neoplasm (MPNs) and myelodysplastic syndromes (MDS) studies presented at the 2020 ASH Annual Meeting. The studies covered first-line and second-line treatments for MPN and MDS as well as therapies to treat the anemia associated with these diseases.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with MDS or MPN do you provide care for in a typical month?

A colleague discusses with you the possibility of managing a patient with polycythemia vera (PV) with off-label interferon but is concerned about long-term toxicity. You discuss the results of the 5-year data from the CONTINUATION-PV study of ropeginterferon α-2b compared with hydroxyurea in patients with treatment-naive PV. Which of the following would you tell your colleague about the safety and efficacy of ropeginterferon α-2b vs hydroxyurea based on the recently reported results from the CONTINUATION-PV study?

You are discussing the data presented at ASH 2020 from the phase II trial of luspatercept in myelofibrosis (MF) with your colleague. Which of the following key findings and implications of this study would you describe to your colleague?

You are discussing clinical trial options with your newly diagnosed patient with higher-risk MDS. One possibility is the phase III PANTHER trial of pevonedistat plus azacitidine. What would you tell your patient about the efficacy and safety of the combination of pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS as seen in the phase II P-2001 study?